z 908

Protesters demand immediate reopening of routes to Parachinar An image from the MWM sit-in in Karachi on December 25, 2024.— Facebook@UlemaOfQom The Majlis Wahdat-e-Muslimeen (MWM) continued their sit-in at Numaish on the fifth consecutive day on Saturday to protest against the Parachinar situation and to express solidarity with the city’s residents. Sit-ins at around 10 other locations across Karachi also continued for a third day. googletag.cmd.push(function() { googletag.display('div-gpt-ad-1700472799616-0'); }); Istehkam-e-Pakistan Party (IPP) Sindh President Mahmood Moulvi, IPP Central Executive Committee member and former Sindh governor Imran Ismail, Muttahida Qaumi Movement-Pakistan (MQM-P) leaders, as well as lawyers and social figures participated in the central sit-in at Numaish and expressed solidarity with the protesters. During his speech at the protest, MWM central leader Allama Hassan Zafar Naqvi responded to Karachi Mayor Barrister Murtaza Wahab’s remarks about the sit-ins. Naqvi claimed that Wahab became mayor through a fake mandate, and that he was speaking the language of the establishment. The MWM leader pointed out that the mayor has not spoken a word about the blockade of Parachinar’s routes for 80 days, during which 130 children died due to the roadblocks. Naqvi said Karachi’s residents are more distressed by the destruction of roads than by sit-ins, adding that the mayor should focus on his work rather than adding salt to the wounds of the victims. He stressed that Karachi has always been the centre of anti-establishment and anti-dictatorship protests. He called for the leadership of the Pakistan Peoples Party (PPP) to take notice of Wahab’s “anti-people” statements. MQM-P leader Shabbir Kaimkhani said on the occasion: “We are Hussaini, and stand against oppression. As a party we have been voicing our concerns against terrorism for the past 40 years. We condemn the incidents of terrorism in Parachinar.” Kaimkhani demanded the immediate opening of the routes to Parachinar, and announced that they would raise an effective voice in the provincial assembly against this injustice. Former governor Ismail said: “The terrorist attack in Parachinar is not the first incident. In Quetta (Balochistan) terrorists had targeted pilgrims. These systematic acts of terrorism are happening in our beloved country.” He said that people adhering to any religion or sect deserve equal rights. “We do not support those spreading sectarianism. We condemn the terrorism in Parachinar, and call for solidarity with its people.” IPP leader Moulvi offered his condolences to the families of the deceased and the injured. “We stand with the people of Parachinar in these difficult times. The current situation is the result of the incompetence of the federal and provincial governments. The routes must be opened.” Other leaders who participated in the protest included MQM-P Rabita Committee member Masood Mahmood, MNA Abdul Hafeez, MPA Anjum Mirza, MPA Amir Siddiqui, Allama Manzoorul Haq Thanvi, Allama Baqar Hussain Zaidi, Allama Nisar Ahmed Qalandri, Maulana Muhammad Hassan Raisi, Shabir Reza, Shamsul Hassan Shamsi, Ishaq Qurayati, Malik Ghulam Abbas and Hassan Sagheer Abdi. The citywide protests have been causing commuters difficulties in reaching their respective destinations despite the fact that the traffic police have announced alternative routes, and have been diverting traffic toward them.Ange Postecoglou is "100 per cent" the right fit for Tottenham - he just needs to translate performances into results. That is the verdict of former Spurs winger Andros Townsend, who is adamant it would represent a mistake if Daniel Levy was to eventually opt for change if fortunes fail to improve. Amazon Prime pundit Townsend said of the club's herky-jerky campaign ahead of today's visit of Wolves : "The way Spurs were before under Jose Mourinho and Antonio Conte, no disrespect, but supporters were crying out for attacking football. "I'm a Spurs fan, I've got loads of Spurs fans that are friends and the one thing they say is we don't care if we lose, we just want to be entertained. That's one thing that Postecoglou will do, he will entertain the fans and they play great football. "The consistency is not there but I think the consistency in how they dominate games and how they throw men forward and how attacking they are is there - it's just the consistency with results. "I think in the Bournemouth game there were three or four goals disallowed by VAR and they dominated Ipswich so I think sometimes the performances are there they just need the results now to follow. For me, Postecoglou has to stay." Surprisingly, scoring goals has been no issue since the devastating departure of Harry Kane to Bayern Munich in 2023. But at the other end, injured-ravaged Tottenham are leaking them for fun and ultimately, that is what is halting their chances of making any notable progress. However, Townsend insists that level of frailty is a historic problem embedded into their DNA. He continued when asked to pinpoint the reason behind their concerning defensive record: "I think it's the way they play even dating back to when I was there many moons ago. "We always used to struggle against the sides at the bottom of the table and beat the sides around the top, it was strange. Now they're so open and so aggressive. "If they're dominating a game they will throw bodies forward until they get their goal and if they're pressing with seven or eight players and a team breaks through the press - like Ipswich did for one of their goals - they're going to concede. "When you've got your first-choice centre-halves injured in Cristian Romero and Micky van de Ven and you've got makeshift players doing a shift for the team, it's always going to be difficult." Mauricio Pochettino achieved consistent results while playing an attractive brand of football, so was he under-appreciated five years on from his dismissal given Spurs now seem to be chasing what they once had at their disposal? Townsend, now playing with Antalyaspor in Turkey, concluded: "The problem with Poch is he did so well that he made getting to a Champions League final seem normal. "That is not normal for Spurs, he did so well, he built up their stature and built Tottenham up to be a team that were in the Champions League every season and fans got too complacent. "I wouldn't say they hounded him out but there was definitely a small section of fans that did want him sacked. "Honestly, he did an amazing job in taking them from what I wouldn't say was mediocrity but I remember the last season before Poch, we lost 5-0 at home to Liverpool and I think we lost 6-0 at Man City. "We were a bit of a laughing stock and five years later, the five-year plan ended with Spurs in a Champions League final. I feel like he's appreciated now but at the time, he wasn't entirely." Andros Townsend was speaking on behalf of Amazon Prime, who aired over 10 hours of live festive football on Boxing Day at no extra cost of their Prime membership. Join our new WhatsApp community! Click this link to receive your daily dose of Mirror Football content. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don’t like our community, you can check out any time you like. If you’re curious, you can read our Privacy Notice.Official Govt & Legal Notices For Dec 18 2024Telecom Application Programming Interface (API) Market to Exhibit a Remarkable CAGR of 20.82% by 2028, Size, Share, Trends, Key Drivers, Demand, Opportunity Analysis and Competitive Outlook 11-26-2024 10:24 PM CET | Advertising, Media Consulting, Marketing Research Press release from: Data Bridge Market Research Telecom application programming interface (API) market size is valued at USD 871.36 million by 2028 is expected to grow at a compound annual growth rate of 20.82% in the forecast period of 2021 to 2028. Telecom application programming interface (API) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, company strengths and weaknesses, product launch, product width and breadth, application dominance. Browse More About This Research Report @ https://www.databridgemarketresearch.com/reports/global-telecom-api-market Some of the major players operating in the Telecom Application Programming Interface (API) market are Vodafone Idea Limited, TWILLO INC., ALE International, AT&T Intellectual Property, Telefonica S.A., Orange, Verizon, Fortumo, LocationSmart, Aspect Software, Vonage, Oracle, Nokia, MuleSoft, LLC, Telefonaktiebolaget LM Ericsson, Cisco Systems, Inc., Google, Huawei Technologies Co., Ltd., Syniverse Technologies LLC, and Persistent Systems among other domestic and global players. Global Telecom Application Programming Interface (API) Market Scope The Telecom Application Programming Interface (API) market is segmented on the basis of offering, equipment , application ,end-user industry . The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications. Offering Hardware Software Services and Solutions Equipment Coordinate Measuring Machine Optical Digitizer and Scanner Measuring Instrument X-Ray and Computed Tomography Automated Optical Inspection 2D Equipment Application Reverse Engineering Quality Control and Inspection Mapping and Modelling Other Applications End-User Industry Aerospace and Defence Automotive Manufacturing Semiconductor Others Browse Trending Reports: https://dbmrblogs02.blogspot.com/2024/11/ammunition-market-trends-forecast-and.html https://dbmrblogs02.blogspot.com/2024/11/thyristor-discrete-semiconductor-market.html https://dbmrblogs02.blogspot.com/2024/11/vaginal-discharge-syndrome-market.html https://dbmrblogs02.blogspot.com/2024/11/single-use-medical-devices-reprocessing.html About Data Bridge Market Research: An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune. Contact Us: - Data Bridge Market Research Email: - sopan.gedam@databridgemarketresearch.com This release was published on openPR.z 908 。

Detroit -- China will soon see a massive expansion of electric vehicle battery swapping, as global battery maker CATL said Wednesday it is investing heavily in stations there next year. Battery swapping is not new — but it's had a challenging journey. Adoption of electric vehicles has varied in regions across the globe over the past several years, and that doesn't always bode well for building new infrastructure. While the technology could do well in China, it's uncertain whether it could work in other countries. Battery swapping allows EV drivers to pull into a station on a low battery and receive a swapped, fully-charged battery within minutes. An EV has to be equipped with the right technology to receive a swap — and not many models around the world currently have it. Automakers have to buy into the idea, and EV adoption among consumers also has to grow, so that investing in new infrastructure seems worthwhile. Consumers also have to be comfortable not owning their battery. China is much further along in adopting EVs than other countries. Not only is it the world's largest auto market, but in July, the country hit a milestone with 50% of new sales electric — and it accounts for most of this year's global EV sales. China supports EV growth through government subsidies and mandates. So it makes more sense for companies to invest in unique EV infrastructure there because that's more likely to be needed. The most notable example might be Israeli startup Better Place, which tried its hand at swapping in 2007. But the company shut down a few years later after investing a lot of money and coming up against roadblocks with logistics. EV adoption was especially low at the time. Startup Ample, for example, has a modular battery swapping station that it says can complete a swap in 5 minutes. That’s important as charging time remains a point of concern for prospective EV buyers. Even the fastest fast chargers could take at least 15 minutes for a decent charge. But in the U.S., pure EVs only accounted for 8% of new vehicle sales as of November. Meanwhile Nio, a rival Chinese EV brand, has about 60 swap stations in northern Europe, and the EV adoption is higher there than the U.S., but the same challenges remain. Different automakers put different batteries in their various EV models, so a station would need all of those available if the industry didn't agree to a standardized battery, and not all of those models are out yet in volume. This is something that really needs scale. Swapping could help with EV cost — currently a barrier to adoption for many — because a driver wouldn’t necessarily own the most expensive part of an EV: the battery. Greg Less, director of the University of Michigan Battery Lab, said with proper framing and education, people might like the idea of battery swapping. To him, it's not unlike buying a propane-fueled grill and purchasing a refilled tank every so often. But it would require a rethinking of car ownership. "Where I could see it working is if we went entirely away from vehicle ownership and we went to a use-on-demand model," Less added. “I don’t think we’re there yet.” Battery swapping might make most sense for ride-sharing or other fleet vehicles. Drivers of buses, taxis, Uber or Lyft vehicles want to spend as much time on the road as possible, transporting customers and making money. If battery swapping can shorten the time needed to charge EVs, that makes driving one less disruptive to their business. ___ Alexa St. John is an Associated Press climate solutions reporter. Follow her on X: @alexa_stjohn . Reach her at ast.john@ap.org . ___ Read more of AP’s climate coverage at http://www.apnews.com/climate-and-environment ___ The Associated Press’ climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP’s standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org .

FOOTBALLER Marcus Rashford is fighting fit — after taking up boxing and mixed martial arts. The Manchester United and England striker , 27, has been working out in a boxing gym. He has also had sessions with a trainer who specialises in Muay Thai, a form of martial arts favoured by cage fighters. Rashford was left out of the England squad for this month’s Nations League games. Instead, he went to New York and watched a UFC cage fight and basketball game. A source said: “Marcus has really started to get into fighting in recent years. “He’s always enjoyed watching boxing with his mates but he’s also developed an interest in MMA as the sport has become more popular. “The club know and have no problem with it. “They just think it’s great extra fitness training.” Rashford is hoping to win the favour of new head coach Ruben Amorim , who backed his recent trip to New York .

CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $

Remembering a Strong Leader: Manmohan Singh's Global LegacyNone